Literature DB >> 30630977

ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity.

Marketa Zaliova1,2,3, Eliska Potuckova4,2, Lenka Hovorkova4,2, Alena Musilova4,2, Lucie Winkowska4,2, Karel Fiser4,2, Jan Stuchly4,2, Ester Mejstrikova4,2,3, Julia Starkova4,2, Jan Zuna4,2,3, Jan Stary2,3, Jan Trka4,2,3.   

Abstract

ERG-deletions occur recurrently in acute lymphoblastic leukemia, especially in the DUX4-rearranged subtype. The ERG-deletion was shown to positively impact prognosis of patients with IKZF1-deletion and its presence precludes assignment into IKZF1 plus group, a novel high-risk category on AIEOP-BFM ALL trials. We analyzed the impact of different methods on ERG-deletion detection rate, evaluated ERG-deletion as a potential marker for DUX4-rearranged leukemia, studied its associations with molecular and clinical characteristics within this leukemia subtype, and analyzed its clonality. Using single-nucleotide-polymorphism array, genomic polymerase chain reaction (PCR) and amplicon-sequencing we found ERG-deletion in 34% (16 of 47), 66% (33 of 50) and 78% (39 of 50) of DUX4-rearranged leukemia, respectively. False negativity of ERG-deletion by single-nucleotide-polymorphism array caused IKZF1 plus misclassification in 5 patients. No ERG-deletion was found outside the DUX4-rearranged cases. Within DUX4-rearranged leukemia, the ERG-deletion was associated with higher total number of copy-number aberrations, and, importantly, the ERG-deletion positivity by PCR was associated with better outcome [5-year event-free survival (EFS), ERG-deletion-positive 93% vs. ERG-deletion-negative 68%, P=0.022; 5-year overall survival (OS), ERG-deletion-positive 97% vs. ERG-deletion-negative 75%, P=0.029]. Ultra-deep amplicon-sequencing revealed distinct co-existing ERG-deletions in 22 of 24 patients. In conclusion, our data demonstrate inadequate sensitivity of single-nucleotide-polymorphism array for ERG-deletion detection, unacceptable for proper IKZF1 plus classification. Even using more sensitive methods (PCR/amplicon-sequencing) for its detection, ERG-deletion is absent in 22-34% of DUX4-rearranged leukemia and does not represent an adequately sensitive marker of this leukemia subtype. Importantly, the ERG-deletion potentially stratifies the DUX4-rearranged leukemia into biologically/clinically distinct subsets. Frequent polyclonal pattern of ERG-deletions shows that late origin of this lesion is more common than has been previously described. Copyright
© 2019 Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30630977      PMCID: PMC6601096          DOI: 10.3324/haematol.2018.204487

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Count-based differential expression analysis of RNA sequencing data using R and Bioconductor.

Authors:  Simon Anders; Davis J McCarthy; Yunshun Chen; Michal Okoniewski; Gordon K Smyth; Wolfgang Huber; Mark D Robinson
Journal:  Nat Protoc       Date:  2013-08-22       Impact factor: 13.491

2.  ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia.

Authors:  M Zaliova; O Zimmermannova; P Dörge; C Eckert; A Möricke; M Zimmermann; J Stuchly; A Teigler-Schlegel; B Meissner; R Koehler; C R Bartram; L Karawajew; P Rhein; J Zuna; M Schrappe; G Cario; M Stanulla
Journal:  Leukemia       Date:  2013-09-27       Impact factor: 11.528

3.  Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.

Authors:  Marketa Zaliova; Lenka Hovorkova; Martina Vaskova; Ondrej Hrusak; Jan Stary; Jan Zuna
Journal:  Genes Chromosomes Cancer       Date:  2016-06-23       Impact factor: 5.006

4.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Authors:  Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

5.  IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Martin Stanulla; Elif Dagdan; Marketa Zaliova; Anja Möricke; Chiara Palmi; Giovanni Cazzaniga; Cornelia Eckert; Geertruy Te Kronnie; Jean-Pierre Bourquin; Beat Bornhauser; Rolf Koehler; Claus R Bartram; Wolf-Dieter Ludwig; Kirsten Bleckmann; Stefanie Groeneveld-Krentz; Denis Schewe; Stefanie V Junk; Laura Hinze; Norman Klein; Christian P Kratz; Andrea Biondi; Arndt Borkhardt; Andreas Kulozik; Martina U Muckenthaler; Giuseppe Basso; Maria Grazia Valsecchi; Shai Izraeli; Britt-Sabina Petersen; Andre Franke; Petra Dörge; Doris Steinemann; Oskar A Haas; Renate Panzer-Grümayer; Hélène Cavé; Richard S Houlston; Gunnar Cario; Martin Schrappe; Martin Zimmermann
Journal:  J Clin Oncol       Date:  2018-03-02       Impact factor: 44.544

6.  An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.

Authors:  E Clappier; M F Auclerc; J Rapion; M Bakkus; A Caye; A Khemiri; C Giroux; L Hernandez; E Kabongo; S Savola; T Leblanc; K Yakouben; G Plat; V Costa; A Ferster; S Girard; O Fenneteau; J M Cayuela; F Sigaux; N Dastugue; S Suciu; Y Benoit; Y Bertrand; J Soulier; H Cavé
Journal:  Leukemia       Date:  2013-09-25       Impact factor: 11.528

7.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

8.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Salil Goorha; Ina Radtke; Christopher B Miller; Elaine Coustan-Smith; James D Dalton; Kevin Girtman; Susan Mathew; Jing Ma; Stanley B Pounds; Xiaoping Su; Ching-Hon Pui; Mary V Relling; William E Evans; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

9.  Intragenic ERG Deletions Do Not Explain the Biology of ERG-Related Acute Lymphoblastic Leukemia.

Authors:  Eliska Potuckova; Jan Zuna; Lenka Hovorkova; Julia Starkova; Jan Stary; Jan Trka; Marketa Zaliova
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

10.  Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.

Authors:  Henrik Lilljebjörn; Rasmus Henningsson; Axel Hyrenius-Wittsten; Linda Olsson; Christina Orsmark-Pietras; Sofia von Palffy; Maria Askmyr; Marianne Rissler; Martin Schrappe; Gunnar Cario; Anders Castor; Cornelis J H Pronk; Mikael Behrendtz; Felix Mitelman; Bertil Johansson; Kajsa Paulsson; Anna K Andersson; Magnus Fontes; Thoas Fioretos
Journal:  Nat Commun       Date:  2016-06-06       Impact factor: 14.919

View more
  8 in total

Review 1.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 2.  IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Authors:  Martin Stanulla; Hélène Cavé; Anthony V Moorman
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

Review 3.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

Review 4.  Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.

Authors:  Yaacov Ben-David; Babu Gajendran; Klarke M Sample; Eldad Zacksenhaus
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

5.  Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.

Authors:  Zhenhua Li; Shawn Hsien Ren Lee; Winnie Hui Ni Chin; Yi Lu; Nan Jiang; Evelyn Huizi Lim; Elaine Coustan-Smith; Kean Hui Chiew; Bernice Ling Zhi Oh; Grace Shimin Koh; Zhiwei Chen; Shirley Kow Yin Kham; Thuan Chong Quah; Hai Peng Lin; Ah Moy Tan; Hany Ariffin; Jun J Yang; Allen Eng-Juh Yeoh
Journal:  Blood Adv       Date:  2021-12-14

Review 6.  The Yin and Yang-Like Clinical Implications of the CDKN2A/ARF/CDKN2B Gene Cluster in Acute Lymphoblastic Leukemia.

Authors:  Celia González-Gil; Jordi Ribera; Josep Maria Ribera; Eulàlia Genescà
Journal:  Genes (Basel)       Date:  2021-01-09       Impact factor: 4.096

Review 7.  Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Monika Lejman; Aleksandra Chałupnik; Zuzanna Chilimoniuk; Maciej Dobosz
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

8.  Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations

Authors:  Željko Antić; Jiangyan Yu; Simon V Van Reijmersdal; Anke Van Dijk; Linde Dekker; Wouter H Segerink; Edwin Sonneveld; Marta Fiocco; Rob Pieters; Peter M Hoogerbrugge; Frank N Van Leeuwen; Ad Geurts Van Kessel; Esme Waanders; Roland P Kuiper
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.